- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04766723
Badanie oceniające skuteczność i bezpieczeństwo NT 201 (toksyny botulinowej) w porównaniu z placebo w leczeniu dorosłych uczestników z drżeniem samoistnym ramienia
Prospektywne, randomizowane, podwójnie ślepe, kontrolowane placebo badanie w grupach równoległych z okresem otwartej próby w celu zbadania skuteczności i bezpieczeństwa NT 201 w jednostronnym i obustronnym leczeniu drżenia samoistnego kończyny górnej
The purpose of this study is to determine whether a single treatment with NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the motor-dominant arm (Unilateral Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.
The following treatment cycle will investigate the safety and tolerability of two-sided treatment with NT 201 (botulinum toxin) (Open Label Bilateral Period). All participants will receive NT 201 treatment.
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Ontario
-
London, Ontario, Kanada, N6A 5A5
- London Health Sciences Centre, Merz Investigational Site #0010087
-
-
-
-
-
Krakow, Polska, 30-539
- Specjalistyczne Gabinety, Merz Investigational Site #0480059
-
Lodz, Polska, 90-640
- NeuroKlinika Gabinet Lekarski, Merz Investigational Site #0480101
-
Oświęcim, Polska, 32-600
- Instytut Zdrowia Dr. Boczarska-Jedynak
-
Warsaw, Polska, 03-242
- Mazowiecki Szpital Bródnowski, Merz Investigational Site #0480064
-
-
-
-
Florida
-
Tampa, Florida, Stany Zjednoczone, 33612
- USF, Department of Neurology, Merz Investigational Site #0010020
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68131
- University of Nebraska Medical Center, Merz Investigational Site #0010269
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89106
- Cleveland Clinic Lou Ruvo Center for Brain Health, Merz Investigational Site #0010457
-
-
New York
-
New York, New York, Stany Zjednoczone, 10029
- Mount Sinai Medical Center, Merz Investigational Site #0010191
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Vanderbilt University Medical Center, Neuroscience Institute, Merz Investigational Site #0010206
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Houston Methodist Neurological Institute, Merz Investigational Site #0010226
-
-
Virginia
-
McLean, Virginia, Stany Zjednoczone, 22101
- Medstar Georgetown Neurology, Merz Investigational Site #0010231
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98195
- UW Medical Center - Montlake, Merz Investigational Site #0010450
-
Spokane, Washington, Stany Zjednoczone, 99202
- Selkirk Neurology, Merz Investigational Site #0010456
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Score of ≥ 2 (at least 1 cm tremor amplitude) in at least two out of three maneuvers of test item 4 (upper limb tremor) of the TETRAS performances scale confirmed by an independent TETRAS expert by means of video assessment.
Exclusion Criteria:
- History or presence of day-to-day fluctuations in ET which would jeopardize meaningful tremor assessment over time, e.g. severe tremor on one day and minimal or no tremor on another day.
- Other neurological signs, such as dystonia, ataxia, or parkinsonism, which in the judgment of the investigator could interfere with the ET diagnosis and/or assessment of ET in ULs.
- Tremor types other than ET
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: NT 201 (IncobotulinumtoxinA, Xeomin)
Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the motor-dominant upper limb. Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of both upper limbs. |
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Inne nazwy:
|
|
Komparator placebo: Placebo
Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the motor-dominant upper limb. Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of both upper limbs. |
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Inne nazwy:
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist
Ramy czasowe: Baseline up to Week 6
|
TremorTek kinematic analytic investigational device is combination of computer software and wearable movement sensors that allows to collect motion data when placed on individual's arm to quantify tremor in various muscle groups that impact shoulder, elbow, wrist. This assessment system was used to measure maximum angular tremor amplitude at wrist of injected limb (unit: degrees). Angular tremor amplitude was measure of tremor severity. Reduction of maximum angular tremor amplitude at wrist of injected limb represented tremor improvement. |
Baseline up to Week 6
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Unilateral Treatment Period: Change From Baseline to Week 6 in the Essential Tremor Rating Assessment Scale (TETRAS) Performance Dominant Upper Limb (UL) Score as Assessed by Investigator
Ramy czasowe: Baseline up to Week 6
|
The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 (including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor. |
Baseline up to Week 6
|
|
Unilateral Treatment Period: Change From Baseline to Week 6 in the TETRAS Activities of Daily Living (ADL) UL Score
Ramy czasowe: Baseline up to Week 6
|
TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items (on UL tremor [items 2-9]). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity. |
Baseline up to Week 6
|
|
Unilateral Treatment Period: Change From Baseline to Week 6 in TETRAS ADL Functional Impact Score
Ramy czasowe: Baseline up to Week 6
|
TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity. |
Baseline up to Week 6
|
|
Unilateral Treatment Period: Subject's Global Impression of Change Scale (GICS) Score of Motor-dominant UL at Week 6
Ramy czasowe: Week 6
|
The GICS was used to evaluate overall clinical impression of change after treatment by the subject. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements. |
Week 6
|
|
Unilateral Treatment Period: Investigator's GICS Score of Motor-dominant UL at Week 6
Ramy czasowe: Week 6
|
The GICS was used to evaluate the overall clinical impression of change after treatment by the investigator. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements. |
Week 6
|
|
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Dominant UL Score
Ramy czasowe: Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
|
TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 ((including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor. |
Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
|
|
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Subscale Score
Ramy czasowe: Baseline of Cycle 2 up to Week 6 (Cycle length =12 weeks)
|
The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. TETRAS performance subscale consisted of 9 items: head, face, and voice tremor (items 1-3), UL tremor of right and left UL (item 4) in three tasks (forward outstretched postural tremor, lateral "wing-beating" postural tremor, kinetic tremor), Archimedes spirals with both hands, handwriting with motor-dominant hand, and dot approximation task with both hands (items 6-8), and lower limb tremor and standing tremor (items 5 and 9). Each item was rated from 0 (no tremor) to 4 (severe tremor) with overall performance score of 0 to 64, calculated as the sum of subscale items. Higher scores indicated greater tremor severity. |
Baseline of Cycle 2 up to Week 6 (Cycle length =12 weeks)
|
|
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL UL Score
Ramy czasowe: Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
|
TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items on UL tremor (items 2-9). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity. |
Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
|
|
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL Functional Impact Score
Ramy czasowe: Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
|
TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity. |
Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
|
|
Percentage of Subjects With At-least One Treatment Related Treatment-emergent Adverse Events (TEAEs)
Ramy czasowe: Unilateral Treatment Period: From first injection in unilateral treatment period up to re-injection in Bilateral Treatment Period (Week 24); Bilateral Treatment Period: From re-injection in Bilateral Treatment Period at Week 24 up to end of study(Week 36)
|
An adverse event (AE) is any untoward medical occurrence in subject administered pharmaceutical product. TEAEs of unilateral treatment period (Cycle 1) = AEs from first injection up to injection in the bilateral treatment period (Week 24). TEAEs of bilateral treatment period (Cycle 2) = AEs from injection in bilateral treatment period up to end of study (Week 36). |
Unilateral Treatment Period: From first injection in unilateral treatment period up to re-injection in Bilateral Treatment Period (Week 24); Bilateral Treatment Period: From re-injection in Bilateral Treatment Period at Week 24 up to end of study(Week 36)
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Merz Medical Expert, Merz Pharmaceuticals GmbH
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- M602011069
- 2021-001988-24 (Numer EudraCT)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .